

1 **Title: The usefulness of antigen testing in predicting contagiousness in COVID-19**

2 **Authors:** Tulio J. Lopera, Juan Carlos Alzate-Ángel, Francisco J, Díaz, María T. Rugeles,
3 Wbeimar Aguilar-Jiménez

4 **Affiliations:**

5 Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
6 (TJ. Lopera, FJ. Díaz, MT. Rugeles, W. Aguilar-Jiménez, JC. Alzate-Ángel)

7 **Abstract**

8 Increasing the diagnostic capacity of COVID-19 (SARS-CoV-2 infection) is required to
9 improve case detection, reduce COVID-19 expansion, and boost the world economy. Rapid
10 antigen detection tests are cheaper and easier to implement, but their diagnostic performance has
11 been questioned compared to RT-PCR. Here, we evaluate the performance of the Standard Q
12 COVID-19 antigen test for diagnosing SARS-CoV-2 infection and predicting contagiousness
13 compared to RT-PCR and viral culture, respectively. The antigen test was 100.0% specific but
14 only 40.9% sensitive for diagnosing infection compared to RT-PCR. Interestingly, SARS-CoV-2
15 contagiousness is highly unlikely with a negative antigen test since it exhibited a negative
16 predictive value of 99.9% than viral culture. Furthermore, a cycle threshold (Ct) value of 18.1 in
17 RT-PCR was shown to be the one that best predicts contagiousness (AUC 97.6%). Thus, screening
18 people with antigen testing is a good approach to prevent SARS-CoV-2 contagion and allow
19 returning to daily activities.

20 **Keywords:** SARS-CoV-2, COVID-19, antigen detection test, isolation viral, RT-PCR

21 **Introduction**

22 Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has resulted in a global
23 health crisis that requires substantial efforts worldwide to increase the diagnosis capacity and

24 improve detection of cases by using inexpensive, easy, and rapid testing (1). On the other hand,
25 the economic re-opening requires a diagnostic test before returning to daily activities. Therefore,
26 a negative result in a diagnostic test has become the entrance door to many countries or to other
27 activities that involve some risk of transmission (2).

28
29 Reverse transcription-polymerase chain reaction (RT-PCR) has become the standard gold
30 test for SARS-CoV-2 detection due to its high sensitivity and specificity (3). However, it has been
31 observed that RT-PCR remains positive well beyond the period of contagiousness. Therefore, the
32 return to daily activities is delayed, generating unnecessary restrictions for patients in the
33 convalescent period. In these patients, viral RNA can be detected in low loads (~Ct value > 24 in
34 RT-PCR), and contagiousness is unlikely. For this reason, classical techniques such as viral
35 isolation are used as a better predictor of viral infectivity. However, these methodologies are
36 expensive, risky, and time-consuming.

37
38 In 2020 point-of-care (POC) tests, such as antigen detection, were developed and approved
39 (4). The first antigen test approved for diagnosis use in Colombia was the Standard Q COVID-19
40 Ag test (SD Biosensor, Republic of Korea), which is based on immunochromatography and
41 detects the nucleocapsid (N) antigen of SARS-CoV-2 using monoclonal antibodies (5). Antigen
42 detection tests have shown desirable diagnostic characteristics such as reasonable specificity, fast
43 execution, and easy processing (5,6).

44
45 The sensitivity and specificity of diagnostic tests are essential parameters used to guide
46 decision-making regarding diagnostic tests. However, antigen tests are considered inferior to RT-

47 PCR because their sensitivity for detecting SARS-CoV-2 is lower (7,8), likely since the
48 performance of antigen tests can be affected by the days of symptoms onset (DSO) and viral load
49 during infection (9,10). Likewise, the usefulness of the antigen test for predicting contagiousness
50 remains to be determined (11). Thus, we aimed to evaluate the performance of a rapid antigen
51 detection test approved for use in Colombia using RT-PCR and viral culture as the standard gold
52 tests for diagnosing infection and contagiousness, respectively.

53

54 **Materials and Methods**

55 **Population**

56 A sample size of at least 250 specimens with a ratio of positive: negative of 1:1 was
57 calculated, anticipating a 97% specificity according to reported previously (12,13), a probability
58 of type I error of 5%, and a precision of 3%. The inclusion criteria to participate in the study were:
59 adults (≥ 18 years) with suspicion of SARS-CoV-2 infection either by clinical or epidemiological
60 criteria (clinical symptoms or recent exposure to a confirmed case, respectively). We analyzed 306
61 nasopharyngeal samples from 282 ambulatory subjects (some were sampled more than once as
62 part of their follow-up) recruited at the Grupo Inmunovirología, University of Antioquia, Medellin,
63 Colombia, between September 2020 and January 2021. We excluded pediatric patients and
64 individuals who were unwilling to provide their written consent. The study was designed and
65 conducted following the Declaration of Helsinki and Colombia legislation (Ministry of Health
66 resolution 008430 of 1993). It was approved by the Ethics Committee of the Universidad de
67 Antioquia (Act. 004, 02-04-2020). After explaining the project and clarifying doubts about the
68 research, all included subjects signed the informed consent. The collected biological material was
69 encoded to ensure privacy.

70

71 **Sample collection**

72 Nasopharyngeal swabs collected on viral transport medium were obtained following the
73 Centers for Disease Control and Prevention (CDC) recommendations (14). The nasopharyngeal
74 samples were maintained at 4°C for 4-84 hours before processing. The epidemiological and
75 demographic data were collected from each subject filling out the official form for reporting acute
76 respiratory infection by SARS-CoV-2 (National Institute of Health, Colombia) (15).

77

78 **Antigen test**

79 We used the Standard Q COVID-19 Ag test (SD Biosensor, Republic of Korea), following
80 the manufacturer's recommendations (6). Briefly, 350µL of the viral transport medium were mixed
81 for 1-10 minutes with the antigen test-lysing reagent. Then, 4 drops were added to the cassette,
82 and after 30 minutes, the test was interpreted as positive, negative, or invalid. The antigen tests
83 were evaluated independently by two laboratory technicians blinded to the RT-PCR and viral
84 culture results. In case of discrepancy, the antigen test was repeated with the same sample.

85

86 **Real-time RT-PCR**

87 Viral RNA extraction was performed from a 300 µL viral transport medium using the
88 column-based Quick-RNA Viral Kit (Zymo Research, Orange, CA) following the manufacturer's
89 instructions. SARS-CoV-2 viral RNA was detected using the Luna® Universal Probe One-Step
90 RT-qPCR Kit (New England Biolabs, MA, USA). The reaction included 7µL of viral RNA, the
91 oligos and probe for the E gene and the conditions reported in the Berlin real-time RT-PCR
92 protocol v2 (16) with a thermal modification in reverse transcription (55°C for 18 minutes) and in

93 alignment/extension step (60°C for 30 seconds), according to the One-Step RT-qPCR Kit
94 manufacturer's recommendations.

95
96 In addition, human RNase P gene transcripts were detected as internal control and
97 evaluation of the quality of the sample, as previously recommended (17). The RT-PCR reactions
98 were carried out in a CFX-96 Biorad thermal cycler (Biorad, CA, USA). Tests were performed in
99 parallel with a negative control (sample replaced by water) and a positive control (RNA from virus
100 isolated at the University of Antioquia) (18).

101

102 **Viral culture**

103 Viral cultures were carried out in a biosafety level 3 laboratory (BSL-3). Approximately
104 100 µL of the viral transport medium was dissolved in 250 µL of DMEM culture medium
105 supplemented with 2% fetal bovine serum and 1% Penicillin-Streptomycin. This solution was
106 inoculated into 1×10^5 Vero E6 cells monolayers in 12-well plates and incubated for 90 min at 37°
107 C with 5% CO₂. Subsequently, the inoculum was removed, and 1,5 mL of DMEM culture medium
108 supplemented with 2% fetal bovine serum and 1% Penicillin-Streptomycin was added. The culture
109 was kept at 37°C with 5% CO₂ for 5 days. The monolayer was observed daily for a cytopathic
110 effect (CPE; observed as rounding and detachment of infected cells) indicative of SARS-CoV-2
111 infection. After CPE observation, the supernatants were harvested and stored at -80°C. For
112 confirmation purposes, some samples with or without CPE were evaluated for the presence of
113 SARS-CoV-2 by indirect immunofluorescence (18) or by qRT-PCR on cell supernatants; all of
114 these samples showed a perfect correlation between the presence of CPE and detection of the virus
115 in the cell culture (data not shown).

116

117 **Statistical analysis**

118 The Standard Q COVID-19 Ag test was evaluated using the sensitivity, specificity,
119 predictive value, and likelihood ratio calculated using GrapdPad Prism (version 9, California,
120 USA), R v4.1.0, and the Integrated Development Environment Rstudio. To explore variables
121 associated with the result of each test, bivariate analyses were carried-out, and according to
122 statistical (p-value <0.05) and plausibility criteria, they were included in a binary logistic
123 regression model. Receiver Operating Characteristic (ROC) curves were constructed to
124 discriminate the best cycle threshold (Ct) value predicting contagiousness.

125

126 **Results**

127 **Demographic and clinical characteristics of the population**

128 In this study, 306 nasopharyngeal samples were analyzed. All samples were blinded and codified
129 before the analyzes. The median age of subjects was 38 years [Range 18 - 96], and 58.9% were
130 female. Considering that the performance of diagnostic tests may fluctuate depending on DSO, we
131 allocate the samples in four diagnostic sceneries: *i*) 108 samples came from subjects with 1-5 DSO,
132 *ii*) 50 from individuals with 6-11 DSO, *iii*) 9 samples were from individuals with more than 11
133 DSO, and *iv*) 139 samples were from SARS-CoV-2-exposed subjects without symptoms (some
134 symptomatic subjects also disclose previous close contact with a person diagnosed with COVID-
135 19) (Figure 1).

136

137 The percentage of positivity in RT-PCR was higher than 70% in individuals with symptoms
138 but below 40% in asymptomatic ones. In contrast, less than 40% positivity by antigen test and viral

139 culture were seen in subjects with either 1-5 or 6-11 DSO, and no positivity was observed in
140 subjects with more than 11 DSO. As expected, the positivity in viral culture decreased as days
141 with symptoms increased (Figure 1).

142

143 The definitive diagnosis of infection was made by RT-PCR. In total, 176 samples were
144 SARS-CoV-2 RT-PCR-positive (57.5% positivity), most of them from outpatients who resolved
145 COVID-19 at home, and seven were from hospitalized patients. The clinical and demographic
146 characteristics of subjects in the study were recorded in search of associations with the result of
147 antigen test (Table S1) and viral culture (Table S2).

148

149 **Performance of antigen test in the diagnosis of infection**

150 People who tested positive by antigen test were older (age median [range] = 45.5 [20.0-96.0]) than
151 people tested negative (age median [range] = 37 [18.0-84.0]), and a higher proportion of them
152 exhibited cough, fever, odynophagia, dyspnea, fatigue, conjunctivitis, headache, and anosmia or
153 ageusia, compared to those with a negative antigen test. No differences in gender between subjects
154 with positive or negative antigen tests were observed (Table S1).

155

156 The performance of the SARS-CoV-2 antigen test for infection diagnosis was evaluated
157 with RT-PCR as the reference standard. From 176 RT-PCR positive specimens, 72 were positive
158 by antigen test, revealing a low sensitivity (40.9%, confidence interval (CI) 95% = 33.6-48.6%).
159 No negative RT-PCR sample was positive in the antigen test, demonstrating high specificity for
160 SARS-CoV-2 infection (100% CI 95% = 96.4%-100%). Indeed, the probability of COVID-19 was
161 high in the participants with a positive result in the antigen test (positive predictive value, PPV

162 100%, CI 95%= 93.7-100%). Nonetheless, the concordance between the antigen test and RT-PCR
163 was generally low, with a kappa index of 0.37 (CI 95%= 0.29-0.44).

164

165 We observed the best performance of antigen test in samples from patients with 1-5 DSO,
166 in which the diagnostic sensitivity was 57.9% (CI 95%= 46.0%-68.9%), the specificity was 100%
167 (CI 95%= 86.7%-100%), and concordance with the RT-PCR using the kappa index was 0.44
168 (CI95%= 0.32-0.58). In patients between 6 and 11 DSO the sensitivity and specificity of the
169 antigen test were 52.4% (CI 95%= 36.6%-67.7%) and 100% (CI 95%= 59.8%-100%),
170 respectively. In asymptomatic subjects, the performance of the antigen test decreased, showing a
171 poor sensitivity (12.0% CI 95%= 5.0%-25.0%), although the specificity was similar to the other
172 categories (100% CI 95%= 94.8-100%) (Table 1).

173

174 **Positivity of Antigen test and viral culture is linked to Ct value in RT-PCR**

175 Considering that the Ct value in RT-PCR is an indicator of viral load, we explored the
176 distribution of Ct values between positive and negative samples by antigen test and viral culture
177 (Figure 2). Interestingly, the Ct values among both antigen test and viral culture had a similar
178 distribution, being lower in samples that tested positive (median Ct value [interquartile range] of
179 15.2 [12.1-18.1] and 13.7 [11.6-15.6] respectively) than in the negative samples (28.93 [16.7-36.6]
180 and 27.47 [11.8-36.6] respectively, Figure 2). Indeed, out of 65 samples with a Ct<20 by RT-PCR,
181 62 (95.4%) were also positive by antigen test, and 51 (78.5%) were also positive by viral culture.

182

183 **Prediction of contagiousness**

184 All samples were assessed by viral culture and antigen test, even when the RT-PCR was
185 negative. SARS-CoV-2 was isolated in 53 (17,3%) of 306 samples (30% when considering only
186 the 176 samples positive by RT-PCR). The clinical and demographic characteristics of population
187 were recorded in search of associations with the result of viral culture, and thus its usefulness to
188 predict contagiousness. People with a positive culture test were older (a median age [range]= 44.0
189 [20.0-96.0] than people without SARS-CoV-2 isolation (a median age [range]= 38.0 [18.0 – 86-
190 0]), and had a significantly higher frequency of fever, cough, odynophagia, fatigue, dyspnea,
191 headache and anosmia or ageusia, compared to those with a negative culture (Table S2).

192
193 We subsequently explored the usefulness of antigen tests in predicting contagiousness, as
194 measured by viral isolation *in vitro* (Table 1). The concordance between viral culture and antigen
195 test was acceptable, with a kappa index of 0.77 (CI95%= 0.68-0.85). Of 53 viral culture-positive
196 samples, 51 were also positive in the antigen test, showing a high sensitivity (96.2% CI 95%=
197 85.9%-99.3%). In addition, we observed a high negative predictive value of 99.1% (CI 95%=
198 96.6%-99.9%) in predicting contagiousness (Table 1). Likewise, we found that the antigen test
199 predicts contagiousness more accurately 1-5 DSO (kappa index of 0.82, CI95%= 0.71-0.93) than
200 6-11 DSO (kappa index of 0.44, CI95%= 0.21-0.67).

201
202 Asymptomatic subjects that were RT-PCR positive, usually have a low viral load (median
203 Ct [interquartile range] = 29.6 [26.79-33.44]); therefore, most samples were negative by antigen
204 test (95.6%) and viral culture (96.4%). Nevertheless, in this group, the sensitivity of the antigen
205 test for contagiousness was high (100% [CI 95%= 46.29%-100%]) (Table 1).

206

207 We carried out a multiple logistic regression model (Table S3) with variables such as the
208 Ct value in RT-PCR, and those showing a crude association with antigen test or viral culture results
209 (Tables S1 and S2). Although positivity in antigen test was associated with positivity in viral
210 culture [crude OR=134.79 (30.45,596.64)], the association was not statistically significant after
211 covariates adjustment [adjusted OR=5.79 (0.5,66.85)] (Table S3). In contrast, the categorized Ct
212 value was associated with the positivity in viral culture after adjustment. Indeed, the samples with
213 a Ct<20 and <15 had adjusted ORs of 25.07 (2.27, 277.23) and 290.45 (17.19, 4907.16)]
214 respectively (Table S3).

215

216 **Predicting contagiousness by RT-PCR**

217 According to the previous findings, the RT-PCR Ct value, as an indicator of viral load,
218 could help predict infection. Therefore, we analyze the Ct value to find the value that best predicts
219 a positive result in viral culture. An analysis of a receiver operating characteristic (ROC curve)
220 was performed, obtaining a Ct value of 18.1 as the best predictor of viral culture result, with an
221 area under the curve (AUC) of 97.6 % (95% CI = 95.6% - 99.5%) (Figure 3). Our results also
222 showed that the highest Ct value where a viral isolate was obtained was 23.5 (Figure 2).

223

224 **Discussion**

225 We evaluated the Standard Q antigen test performance to diagnose SARS-CoV-2 infection
226 and predict contagiousness. This rapid and simple antigen test is widely used in Colombia and
227 other countries, especially in high prevalence populations; its sensitivity has varied widely across
228 different evaluations (13,16,19–22). In this study, the sensitivity for infection diagnosis in all
229 samples was low, 40.9% (CI 95%= 33.6,48.6%), much lower than the 84% sensitivity reported by

230 the manufacturer (6). Nevertheless, other authors have reported significant variation in sensitivity
231 ranging between 42.9% (23), 70.7% (24), and 98.3% (16).

232
233 This variability seems to be only partially explained by the DSO at sampling because the
234 sensitivity of antigen test in subjects with 1-5 DSO increases up to 57%, whereas in subjects with
235 6-11 DSO the sensitivity was 52%. Indeed, other studies have reported similar sensitivity values
236 in subjects with ≤ 14 DSO (55.4%) (22). On the other hand, our sampling population consists
237 mostly of outpatients, which usually have mild disease and consequently lower viral load.
238 Actually, we observed similar sensitivity compared to 63% reported in patients with the same
239 disease spectrum (25). Indeed, when we evaluated the performance of the antigen test compared
240 to the Ct in RT-PCR, the proportion of positive antigen test was 62/65 (95.4%) in samples with
241 Ct<20, in concordance with other reports indicating around 95% sensitivity of antigen test in
242 samples with high viral load (Ct less than 22.5) (26,27).

243
244 Although the sensitivity of the antigen test was low, its high specificity and high positive
245 predictive value indicate that a positive result in this test provides reliable evidence of SARS-CoV-
246 2 infection; conversely, a negative result does not rule out infection. However, additional testing
247 in subjects with a negative antigen test could be unnecessary if we are interested in detecting
248 patients who are shedding viruses and therefore are a threat to those close to them.

249
250 Remarkably, the antigen test and viral culture performance were similar; in both cases, the
251 distribution of Ct values had a median <20 in positive results. Whereas there were no specific
252 symptoms typical in COVID-19 or DSO related to the probability of viral isolation, the antigen

253 test showed a specificity of 91% to predicts viral infectivity; from the 306 samples, only 2 were
254 discordant between antigen test and viral culture results. In addition, our findings are consistent
255 with studies such as Pekosz *et al* (28), who reported that the antigen tests correlate with viral
256 culture of SARS-CoV-2 in 27/28 samples assessed. Yamayoshi *et al* (26), in samples with a Ct
257 value <22.5 found that antigen test result was similar to viral isolation in culture (11/11 were
258 positive in antigen test and 8/11 in viral culture). Therefore, these results suggest that an antigen
259 test is a promising tool to discharge patients from quarantine because of the low probability of
260 transmitting the virus.

261
262 Although viral culture is the most obvious method to assess contagiousness, it is complex,
263 expensive, and requires particular biosafety conditions. The Ct value of RT-PCR, despite the
264 usefulness in the prediction of contagiousness in samples with high viral load, is intrinsically
265 variable (25,29,30). The variation in Ct can be due to the conditions of the RT-PCR reaction, the
266 fluorescence threshold, the fluorochrome used, the gene target, and the virus lineage (10). Antigen
267 test, which targets the more conserved nucleocapsid protein, is potentially a more consistent and
268 cost/benefit method of assessing contagiousness.

269
270 Although some authors have reported viral isolation in culture up to Ct value close to 32
271 (25,31,32), most studies have associated viral isolation with Ct 18-24 (5.4 – 7.0 log RNA copies)
272 (33,34). Our study indicates that the Ct value that best predicts the result in viral culture is 18.1,
273 with a progressive decrease in the possibility of contagiousness above this Ct value. Hence, we
274 propose that a Ct value higher than 23.5 could be a safe threshold of contagiousness since it was
275 the highest Ct in which we could isolate the virus in culture.

276

277 In this study, the time of exposure was not controlled since it was reported by each
278 individual, considered from the last contact with someone with a COVID-19 confirmed diagnosis.
279 Due to this, many individuals did not know precisely the time of exposure to the virus.
280 Additionally, the data correspond to a study of diagnostic tests in which the prevalence of infection
281 is given by the proportion of infected and uninfected subjects who participated in the study, which
282 could not be an exact reflection of the actual prevalence in the population. Further studies should
283 include a serial sampling of the participants in other prevalence scenarios to improve the scope of
284 the results.

285

286 **Conclusion**

287 This study demonstrated that the Standard Q COVID-19 antigen test has excellent
288 agreement with viral culture, indicating that it can be used as a marker of contagiousness. Due to
289 its high positive predictive value in situations of a high prevalence of infection, positive results do
290 not require confirmation with another test. Likewise, its high negative predictive value for
291 contagiousness makes it possible to use this test as a criterion to discharge patients in isolation and
292 screen people moving into environments that could facilitate the transmission of the virus.
293 Additionally, we found that 18.1 is the Ct value in RT-PCR that best predicts the possibility of *in*
294 *vitro* viral isolation, related to a higher probability of contagion and viral transmission.

295

296 **Acknowledgments**

297 The authors thank the patients and volunteers who kindly participated in this study. We also thank
298 the clinicians who support the recruitment of patients and laboratory assistants who contributed to
299 the sampling.

300 **Funding:**

301 This research was funded by Universidad de Antioquia (UdeA responde al COVID-19) and Grupo
302 Inmunovirología, Facultad de Medicina, Universidad de Antioquia.

303 **Author Contributions:**

304 “Conceptualization, T.J.L, F.J.D, J.C.A, M.T.R, and W.A.J.; methodology, T.J.L, and W.A.J.;
305 formal analysis, J.C.A, T.J.L, and W.A.J; writing—original draft preparation, T.J.L, J.C.A, and
306 W.A.J; writing—review and editing, M.T.R, J.C.A., F.J.D., and W.A.J. All authors have read and
307 agreed to the published version of the manuscript.”

308 **References**

- 309 1. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, et al. Diagnostic
310 Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review.
311 *Ann Intern Med.* 2020 Jun;172(11):726–34.
- 312 2. Oztig LI, Askin OE. Human mobility and coronavirus disease 2019 (COVID-19): a
313 negative binomial regression analysis. *Public Health.* 2020 Aug; 185:364–7.
- 314 3. Organization WH. Diagnostic testing for SARS-CoV-2: interim guidance, 11 September
315 2020. World Health Organization; 2020.
- 316 4. Organization WH. Antigen-detection in the diagnosis of SARS-CoV-2 infection using
317 rapid immunoassays: interim guidance, 11 September 2020 [Internet]. Geneva PP - Geneva:
318 World Health Organization; Available from: <https://apps.who.int/iris/handle/10665/334253>

- 319 5. Mercado Reyes M et al. Validación secundaria y verificación del desempeño de la prueba.
320 2020;(293):1–7.
- 321 6. SD, BIOSENSOR. STANDARDTM Q COVID-19 Ag Test. 2020.
- 322 7. Corman VM, Haage VC, Bleicker T, Schmidt ML, Mühlemann B, Zuchowski M, et al.
323 Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-
324 center laboratory evaluation study. *The Lancet Microbe*. 2021;5247(21):1–9.
- 325 8. Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, et al. Rapid, point-of-
326 care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection [Internet]. Vol.
327 8, *The Cochrane database of systematic reviews*. Test Evaluation Research Group, Institute of
328 Applied Health Research, University of Birmingham, Birmingham, UK.; 2020. p. CD013705.
329 Available from: <http://europepmc.org/abstract/MED/32845525>
- 330 9. Linares M, Pérez-Tanoira R, Carrero A, Romanyk J, Pérez-García F, Gómez-Herruz P, et
331 al. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days
332 after the onset of symptoms. *J Clin Virol Off Publ Pan Am Soc Clin Virol*. 2020 Dec;
333 133:104659.
- 334 10. Rabaan AA, Tirupathi R, Sule AA, Aldali J, Mutair AA, Alhumaid S, et al. Viral
335 Dynamics and Real-Time RT-PCR Ct Values Correlation with Disease Severity in COVID-
336 19. Vol. 11, *Diagnostics*. 2021.
- 337 11. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-
338 2: A Review of Viral, Host, and Environmental Factors. *Ann Intern Med*. 2021 Jan;174(1):69–
339 79.

- 340 12. ICMR. Advisory on Use of Rapid Antigen Detection Test for COVID-19. 2020;1–
341 3. Available from:
342 https://www.icmr.gov.in/pdf/covid/strategy/Advisory_for_rapid_antigen_test14062020.pdf
- 343 13. Chaimayo C, Kaewnaphan B, Tanlieng N, Ahipanyasilp N, Sirijatuphat R,
344 Chayakulkeeree M, et al. Rapid SARS-CoV-2 antigen detection assay in comparison with real-
345 time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand. *Virology* [Internet].
346 2020;17(1):1–7. Available from: <https://doi.org/10.1186/s12985-020-01452-5>
- 347 14. CDC. Interim Guidelines for Collecting and Handling of Clinical Specimens for
348 COVID-19 Testing: Updated Feb. 26, 2021. *Centers Dis Control Prev* [Internet]. 2021;1–6.
349 Available from: [https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-](https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html)
350 [specimens.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html)
- 351 15. Instituto Nacional de Salud. Ficha de notificación individual – Infección
352 respiratoria aguda por virus nuevo. 2020;2019.
- 353 16. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al.
354 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*
355 [Internet]. 2020;25(3). Available from:
356 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.3.2000045>
- 357 17. Palacio Rua K, García Correa JF, Aguilar-Jiménez W, Afanador Ayala C, Rugeles
358 MT, Zuluaga AF. Validación de una técnica de PCR dúplex usando el gen E y RNasa P para
359 el diagnóstico de SARS-CoV-2. *Enferm Infecc Microbiol Clin* [Internet]. 2021; Available
360 from: <https://www.sciencedirect.com/science/article/pii/S0213005X21000197>
- 361 18. Díaz FJ, Aguilar-Jiménez W, Flórez-Álvarez L, Valencia G, Laiton-Donato K,
362 Franco-Muñoz C, et al. Aislamiento y caracterización de una cepa temprana de SARS-CoV-2

- 363 durante la epidemia de 2020 en Medellín, Colombia. *Biomédica* [Internet]. 2020;40(Supl.
364 2):148–58. Available from:
365 <https://revistabiomedica.org/index.php/biomedica/article/view/5834>
- 366 19. Homza M, Zelena H, Janosek J, Tomaskova H, Jezo E, Kloudova A, et al. Five
367 antigen tests for sars-cov-2: Virus viability matters. *Viruses*. 2021;13(4):1–9.
- 368 20. Jegerlehner S, Suter-Riniker F, Jent P, Bittel P, Nagler M. Diagnostic accuracy of
369 a SARS-CoV-2 rapid antigen test in real-life clinical settings. *Int J Infect Dis IJID Off Publ*
370 *Int Soc Infect Dis*. 2021 Aug; 109:118–22.
- 371 21. Hayer J, Kasapic D, Zemmrich C. Real-world clinical performance of commercial
372 SARS-CoV-2 rapid antigen tests in suspected COVID-19: A systematic meta-analysis of
373 available data as of November 20, 2020. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2021
374 Jul; 108:592–602.
- 375 22. Hirotsu Y, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, et al.
376 Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative
377 RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients. *Int*
378 *J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2020 Oct; 99:397–402.
- 379 23. Korenkov M, Poopalasingam N, Madler M, Vanshylla K, Eggeling R, Wirtz M, et
380 al. Evaluation of a Rapid Antigen Test To Detect SARS-CoV-2 Infection and Identify
381 Potentially Infectious Individuals. *J Clin Microbiol*. 2021;59(9).
- 382 24. Krüger LJ, Gaeddert M, Köppel L, Brümmer LE, Gottschalk C, Miranda IB, et al.
383 Evaluation of the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting
384 point-of-care diagnostics for SARS-CoV-2; medRxiv [Internet]. 2020

- 385 Jan 1;2020.10.01.20203836. Available from:
386 <http://medrxiv.org/content/early/2020/10/04/2020.10.01.20203836.abstract>
- 387 25. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al.
388 Viral RNA load as determined by cell culture as a management tool for discharge of SARS-
389 CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis*.
390 2020;39(6):1059–61.
- 391 26. Yamayoshi S, Sakai-Tagawa Y, Koga M, Akasaka O, Nakachi I, Koh H, et al.
392 Comparison of rapid antigen tests for covid-19. *Viruses*. 2020;12(12):1–8.
- 393 27. Hirotsu Y, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, et al.
394 Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative
395 RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients. *Int*
396 *J Infect Dis* [Internet]. 2020; 99:397–402. Available from:
397 <https://doi.org/10.1016/j.ijid.2020.08.029>
- 398 28. Pekosz A, Parvu V, Li M, Andrews JC, Manabe YC, Kodsí S, et al. Antigen-Based
399 Testing but Not Real-Time Polymerase Chain Reaction Correlates with Severe Acute
400 Respiratory Syndrome Coronavirus 2 Viral Culture. *Clin Infect Dis*. 2021;21205(Xx):1–6.
- 401 29. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, et al.
402 Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of
403 COVID-19, England, January to May 2020. *Euro Surveill Bull Eur sur les Mal Transm = Eur*
404 *Commun Dis Bull*. 2020 Aug;25(32).
- 405 30. Bhat TA, Kalathil SG, Bogner PN, Blount BC, Goniewicz ML, Thanavala YM. An
406 Animal Model of Inhaled Vitamin E Acetate and EVALI-like Lung Injury. *N Engl J Med*.
407 2020;382(12):1175–7.

- 408 31. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.
409 Virological assessment of hospitalized cases of coronavirus disease 2019. medRxiv. 2020;
- 410 32. Jeong HW, Kim S, Kim H, Kim Y, Kim JH, Cho JY, et al. Viable SARS-CoV-2 in
411 various specimens from COVID-19 patients. 2020;(January).
- 412 33. L’Huillier AG, Torriani G, Pigny F, Kaiser L, Eckerle I. Culture-Competent SARS-
413 CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents. Emerg Infect
414 Dis. 2020;26(10):2494–7.
- 415 34. Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, et al. Quantitative Detection and
416 Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clin Infect Dis [Internet]. 2020 Jul
417 28;71(15):793–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/32221523>

418

419 Address for correspondence: Wbeimar Aguilar-Jiménez, Grupo Inmunovirología, Facultad de
420 Medicina, Universidad de Antioquia, Medellín, Colombia.

421 Email: Wbeimar.aguilar@udea.edu.co

422

423 **Figure 1: Positivity (%) of each test according to DSO or asymptomatic condition:** figure
424 shows the percentage of positive results obtained by RT-PCR, antigen test, and viral culture in
425 patients who were on 1-5 days of symptom onset (DSO), 6-11 DSO, >11 DSO, and people who
426 were asymptomatic individuals.

427


428 **Figure 2: Ct values according to results in the antigen test and viral culture:** Figure displays
429 the distribution according to of cycle threshold (Ct) value obtained in RT-PCR of positive and
430 negative results of antigen test and viral culture in patients with SARS-CoV-2 infection.


431 **Figure 3. ROC Curve and AUC to calculate the discriminatory Ct value in contagiousness.**

432 The Receiver operating characteristic (ROC) curve shows the Ct value where sensitivity and

433 specificity are higher than 95% to predict the contagiousness using viral culture as reference. Area

434 Under the Curve (AUC) 97.6% (95.6%-99.5%).





1 **Manuscript: The usefulness of antigen testing in predicting contagiousness in**
 2 **COVID-19**
 3 **Table 1: Performance of antigen test, viral culture and RT-PCR in diagnosis of**
 4 **infection and prediction of contagiousness of SARS-CoV-2**

Sceneries	Sensitivity (CI 95%)	Specificity (CI 95%)	VP+ (CI 95%)	VP- (CI 95%)	LR+ (CI 95%)	LR- (CI 95%)
Comparison antigen test vs RT-PCR (reference)						
All subjects	40.9 (33.6,48.6)	100 (96.4,100)	100 (93.68,100)	55.0 (48.0, 61.0)	107.31 (6.7, 1716.2)	0.59 (0.52, 0.7)
1-5 DSO	57.9 (46.0,68.9)	100 (86.7,100)	1.00 (0.89,1.00)	50.0 (38.0, 61.0)	38.14 (2.4, 601.05)	0.42 (0.32, 0.5)
6-11 DSO	52.4 (36.6,67.7)	100 (59.7,100)	100 (81.0, 100)	28.0 (13.0, 48.0)	9.41 (0.6, 141.4)	0.47(0.3, 0.6)
Asymptomatic	12.00 5.0,25.00)	100 (94.8,100)	100 (51.0, 100)	66.0 (58.0, 74.0)	22.94 (1.3, 398.9)	0.88 (0.8, 0.9)
Comparison antigen test vs viral culture (reference)						
All subjects	96.2 (85.9,99.3)	91.0 (87.0,94.0)	70.0 (58.0,80.0)	99.14 96.6,99.9)	11.6 (7.7, 17.5)	0.0 (0.0, 0.2)
1-5 DSO	97.0 (84.0, 99.0)	88.0 (78.0,94.0)	81.0 (66.0,91.0)	98.0 (90.0, 99.0)	8.6 (4.5, 16.6)	0.0 (0.0, 0.2)
6-11 DSO	90.0 (57.0, 99.0)	69.0 (52.0,82.0)	45.0 (25.0,67.0)	96.0 (79.0, 99.0)	3.0 (1.8, 4.9)	0.1 (0.0, 0.9)
Asymptomatic	100 (46.3,100)	99.0 (95.0,99.0)	83.0 (36.0,99.0)	100 (96.0, 100)	134.0 (19.0,944.3)	0.1 (0.0, 1.2)
Comparison RT-PCR vs viral culture (reference)						
All subjects	100 (91.0, 100)	51.0 (45.0, 57.0)	30.0 (23.0,37.0)	100 (96.0, 100)	2.1 (1.8, 2.3)	0.0 (0.0, 0.3)
1-5 DSO	100 (88.0, 100)	45.0 (33.0,57.0)	48.0 (37.0,60.0)	100 (86.0, 100)	1.8 (1.5, 2.2)	0.0 (0.0, 0.5)
6-11 DSO	100 (67.0, 100)	20.0 (9.0, 36.0)	26.0 (14.0,0.42)	100 (59.0, 100)	1.25 (1.1, 1.5)	0.2 (0.0, 3.2)
Asymptomatic	100 (46.0, 100)	66.0 (57.0,74.0)	10.0 (3.0, 22.0)	100 (94.0, 100)	3.0 (2.3, 3.8)	0.1 (0.0, 1.8)

5

6

